IMCR insider transaction filings
Immunocore Holdings plc — 46 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-05-28. Screen IMCR transaction legs live →
Insider transaction summary — last 90 days
No Form 4 filings for IMCR between 2026-06-24 and 2026-09-22. The table below lists the most recent filings on record.
Recent Form 4 filings — Immunocore Holdings plc
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-05-28 | 4 | Bell John Irving — Director | Grant/award (A): 27,492 (derivative) @ $0 | EDGAR |
| 2026-05-28 | 4 | Kaul Siddharth — Director | Grant/award (A): 27,492 (derivative) @ $0 | EDGAR |
| 2026-05-28 | 4 | Herbst Roy Steven — Director | Grant/award (A): 27,492 (derivative) @ $0 | EDGAR |
| 2026-05-28 | 4 | Ratcliffe Peter John — Director | Grant/award (A): 27,492 (derivative) @ $0 | EDGAR |
| 2026-05-28 | 4 | Pao William — Director | Grant/award (A): 27,492 (derivative) @ $0 | EDGAR |
| 2026-05-28 | 4 | Peterson Kristine — Director | Grant/award (A): 27,492 (derivative) @ $0 | EDGAR |
| 2026-02-19 | 4 | St Leger Tina Amber — CHIEF HR OFFICER | Option exercise (M): 2,119 @ $0 · Sale (S): 1,000 @ $32.35 · Option exercise (M): 2,119 (derivative) @ $0 | EDGAR |
| 2026-02-19 | 4 | Coy Travis Alan — Chief Financial Officer | Grant/award (A): 33,353 (derivative) @ $0 · Grant/award (A): 95,637 (derivative) @ $0 | EDGAR |
| 2026-02-19 | 4 | Berman David M — HEAD OF R&D | Option exercise (M): 11,824 @ $0 · Sale (S): 5,965 @ $32.35 · Option exercise (M): 11,824 (derivative) @ $0 | EDGAR |
| 2026-02-19 | 4 | GOLL JOHN — SVP, FINANCE & CAO | Option exercise (M): 1,351 @ $0 · Sale (S): 698 @ $32.35 · Option exercise (M): 1,351 (derivative) @ $0 · Grant/award (A): 7,411 (derivative) @ $0 · Grant/award (A): 21,252 (derivative) @ $0 | EDGAR |
| 2026-02-19 | 4 | Jallal Bahija — CHIEF EXECUTIVE OFFICER, Director | Option exercise (M): 23,817 @ $0 · Sale (S): 11,474 @ $32.35 · Option exercise (M): 23,817 (derivative) @ $0 · Grant/award (A): 88,573 (derivative) @ $0 · Grant/award (A): 395,066 (derivative) @ $0 | EDGAR |
| 2025-12-08 | 4 | Berman David M — HEAD OF R&D | Option exercise (M): 31,341 @ $17.46 · Sale (S): 31,341 @ $40.26 · Option exercise (M): 572 @ $17.46 · Sale (S): 572 @ $40.14 · Option exercise (M): 31,341 (derivative) @ $0 · Option exercise (M): 572 (derivative) @ $0 | EDGAR |
| 2025-12-01 | 4 | Berman David M — HEAD OF R&D | Option exercise (M): 69,404 @ $17.46 · Sale (S): 69,404 @ $40.12 · Option exercise (M): 5,521 @ $17.46 · Sale (S): 5,521 @ $40.09 · Option exercise (M): 69,404 (derivative) @ $0 · Option exercise (M): 5,521 (derivative) @ $0 | EDGAR |
| 2025-11-26 | 4 | Berman David M — HEAD OF R&D | Option exercise (M): 100 @ $17.46 · Sale (S): 100 @ $40 · Option exercise (M): 18,020 @ $17.46 · Sale (S): 18,020 @ $40.03 · Option exercise (M): 100 (derivative) @ $0 · Option exercise (M): 18,020 (derivative) @ $0 | EDGAR |
| 2025-10-02 | 4 | Berman David M — HEAD OF R&D | Option exercise (M): 61,849 @ $17.46 · Sale (S): 61,849 @ $35.23 · Option exercise (M): 61,849 (derivative) @ $0 | EDGAR |
| 2025-09-16 | 4 | Berman David M — HEAD OF R&D | Option exercise (M): 22,532 @ $17.46 · Sale (S): 21,232 @ $35.63 · Sale (S): 1,300 @ $36.31 · Option exercise (M): 200 @ $17.46 · Sale (S): 200 @ $35.01 · Option exercise (M): 22,532 (derivative) @ $0 · +1 more | EDGAR |
| 2025-09-12 | 4 | Berman David M — HEAD OF R&D | Option exercise (M): 31,338 @ $17.46 · Sale (S): 30,138 @ $36.12 · Sale (S): 1,200 @ $36.77 · Option exercise (M): 19,081 @ $17.46 · Sale (S): 19,081 @ $36.28 · Option exercise (M): 31,338 (derivative) @ $0 · +1 more | EDGAR |
| 2025-05-19 | 4 | Ratcliffe Peter John — Director | Grant/award (A): 26,198 (derivative) @ $0 | EDGAR |
| 2025-05-19 | 4 | Pao William — Director | Grant/award (A): 26,198 (derivative) @ $0 | EDGAR |
| 2025-05-19 | 4 | Herbst Roy Steven — Director | Grant/award (A): 26,198 (derivative) @ $0 | EDGAR |
| 2025-05-19 | 4 | Kaul Siddharth — Director | Grant/award (A): 26,198 (derivative) @ $0 | EDGAR |
| 2025-05-19 | 4 | Bell John Irving — Director | Grant/award (A): 26,198 (derivative) @ $0 | EDGAR |
| 2025-05-19 | 4 | Peterson Kristine — Director | Grant/award (A): 26,198 (derivative) @ $0 | EDGAR |
| 2025-05-19 | 4 | BAKER BROS. ADVISORS LP — Director 667, L.P. — Director Baker Bros. Advisors (GP) LLC — Director Baker Brothers Life Sciences LP — Director BAKER FELIX — Director BAKER JULIAN — Director | Grant/award (A): 26,198 (derivative) @ $0 · Grant/award (A): 26,198 (derivative) @ $0 | EDGAR |
| 2025-03-19 | 4 | BAKER BROS. ADVISORS LP — Director 667, L.P. — Director Baker Bros. Advisors (GP) LLC — Director Baker Brothers Life Sciences LP — Director BAKER FELIX — Director BAKER JULIAN — Director | Purchase (P): 60,110 @ $29.74 · Purchase (P): 646,290 @ $29.74 · Purchase (P): 8,589 @ $29.56 · Purchase (P): 92,349 @ $29.56 · Sale (S) @ $10,533,376.12 · Sale (S) @ $113,252,773.88 | EDGAR |
| 2025-02-27 | 4 | Pao William — Director | Grant/award (A): 24,443 (derivative) @ $0 | EDGAR |
| 2025-02-19 | 4 | St Leger Tina Amber — CHIEF HR OFFICER | Grant/award (A): 23,212 (derivative) @ $0 · Grant/award (A): 8,476 (derivative) @ $0 | EDGAR |
| 2025-02-19 | 4 | GOLL JOHN — SVP, FINANCE & CAO | Grant/award (A): 14,802 (derivative) @ $0 · Grant/award (A): 5,405 (derivative) @ $0 | EDGAR |
| 2025-02-19 | 4 | Berman David M — HEAD OF R&D | Grant/award (A): 129,518 (derivative) @ $0 · Grant/award (A): 47,297 (derivative) @ $0 | EDGAR |
| 2025-02-19 | 4 | Jallal Bahija — CHIEF EXECUTIVE OFFICER, Director | Grant/award (A): 405,824 (derivative) @ $0 · Grant/award (A): 95,270 (derivative) @ $0 | EDGAR |
| 2025-01-03 | 4 | Coy Travis Alan — Chief Financial Officer | Grant/award (A): 274,033 (derivative) @ $0 | EDGAR |
| 2024-05-29 | 4 | BAKER BROS. ADVISORS LP — Director 667, L.P. — Director Baker Bros. Advisors (GP) LLC — Director Baker Brothers Life Sciences LP — Director BAKER FELIX — Director BAKER JULIAN — Director | Grant/award (A): 12,925 (derivative) @ $0 · Grant/award (A): 12,925 (derivative) @ $0 | EDGAR |
| 2024-05-28 | 4 | Kaul Siddharth — Director | Grant/award (A): 14,534 (derivative) @ $0 | EDGAR |
| 2024-05-28 | 4 | Ratcliffe Peter John — Director | Grant/award (A): 14,534 (derivative) @ $0 | EDGAR |
| 2024-05-28 | 4 | Herbst Roy Steven — Director | Grant/award (A): 14,534 (derivative) @ $0 | EDGAR |
| 2024-05-28 | 4 | Bell John Irving — Director | Grant/award (A): 14,534 (derivative) @ $0 | EDGAR |
| 2024-05-28 | 4 | Peterson Kristine — Director | Grant/award (A): 14,534 (derivative) @ $0 | EDGAR |
| 2024-04-03 | 4 | St Leger Tina Amber — CHIEF HR OFFICER | Option exercise (M): 4,375 @ $29.87 · Sale (S): 4,375 @ $64.06 · Option exercise (M): 4,375 (derivative) @ $0 | EDGAR |
| 2024-03-01 | 4 | Berman David M — HEAD OF R&D | Option exercise (M): 36,509 @ $17.46 · Sale (S): 16,900 @ $67.61 · Sale (S): 7,472 @ $68.84 · Sale (S): 10,937 @ $69.73 · Sale (S): 1,200 @ $70.45 · Option exercise (M): 36,509 (derivative) @ $0 | EDGAR |
| 2024-02-28 | 4 | Berman David M — HEAD OF R&D | Option exercise (M): 28,553 @ $17.46 · Sale (S): 26,516 @ $70.60 · Sale (S): 2,037 @ $71.31 · Option exercise (M): 54,938 @ $17.46 · Sale (S): 4,448 @ $69.45 · Sale (S): 21,152 @ $70.42 · +4 more | EDGAR |
| 2024-02-21 | 4 | GOLL JOHN — SVP, FINANCE & CAO | Grant/award (A): 4,930 (derivative) @ $0 | EDGAR |
| 2024-02-21 | 4 | St Leger Tina Amber — CHIEF HR OFFICER | Grant/award (A): 14,162 (derivative) @ $0 | EDGAR |
| 2024-02-21 | 4 | Di Donato Brian — CHIEF FINANCIAL OFFICER | Grant/award (A): 66,746 (derivative) @ $0 | EDGAR |
| 2024-02-21 | 4 | Berman David M — HEAD OF R&D | Grant/award (A): 111,244 (derivative) @ $0 | EDGAR |
| 2024-02-21 | 4 | Jallal Bahija — CHIEF EXECUTIVE OFFICER, Director | Grant/award (A): 281,819 (derivative) @ $0 | EDGAR |
| 2024-01-05 | 4 | St Leger Tina Amber — Chief HR Officer | Option exercise (M): 4,375 @ $29.87 · Sale (S): 4,068 @ $69.85 · Sale (S): 307 @ $70.46 · Option exercise (M): 4,375 (derivative) @ $0 | EDGAR |
Recent 8-K events — Immunocore Holdings plc
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-14 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-27 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-25 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-30 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-01-09 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-28 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2025-11-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=IMCR returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →